Post-trial access to treatment
Corporate best practices
Published on:
The paper Post-Trial Acces To Treatment (PTA) offers an insight into current corporate policies and corporate best practices relating to the provision of PTA in low and middle income countries based on company sources. In these countries there is a greater appeal for pharmaceutical companies to take responsibility for providing PTA. However, the practice of providing PTA is the exception rather than the rule.
Do you need more information?
-
Irene Schipper
Senior Researcher
Publication
Related content
-
Sector profile of the pharmaceutical industry Published on:F. WeyzigPosted in category:PublicationF. Weyzig
-
-
EU health data law rolls out the red carpet for Big TechPosted in category:Long read
Irene SchipperPublished on:
